pembrolizumab,IMM60
merck,Portage
['lung', 'melanoma', 'portage']
$prtg portage biotech reports updated interim data for lead inkt engager, port-2, in a phase 1/2 trial for the treatment of advanced melanoma and metastatic non-small cell lung cancer at the 2023 american society for clinical oncology (asco) annual meeting 
News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities